background: patients with unresectable colorectal liver metastases (CLM) receiving palliative chemotherapy have a 5-year overall survival (OS) of less than 30%. liver transplantation (LT) can improve OS up to 60%-83% (SECA-I and SECA-II trials). the aim of the study is to assess the efficacy of LT in liver-only metastatic CRC compared with a matched cohort of patients included in a phase III trial on triplet chemotherapy + antiEGFR. patients and methods: the COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial (clinical trials.gov NCT03803436). hyperselected patients with liver-limited unresectable CLM, RAS and BRAF wild-type and curatively removed primary colon cancer are included. the observed post-transplant outcomes will be prospectively compared 1:5 with those obtained in a matched cohort from the TRIPLETE trial (NCT03231722). results: primary endpoint is to compare the 3 and 5-years OS of patients enrolled in the COLT trial with COLT-eligible population enrolled in the TRIPLETE trial. An expected gain in OS of 40% at 5-years is predicted for the COLT population (the expected OS at 5-years in COLT vs. TRIPLETE is 70% vs. 30%). secondary endpoints are to compare the 5-years disease-free survival and to assess the safety of LT dindo-clavien classification and the comprehensive complication Index). conclusion: LT offers the longest OS reported in selected patients with CLM. Improving the selection strategies can give patients a 5-year OS similar to other indications for LT and a better outcome than those undergoing chemotherapy alone.
Sposito, C., Pietrantonio, F., Maspero, M., Di Benedetto, F., Vivarelli, M., Tisone, G., et al. (2023). Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial). CLINICAL COLORECTAL CANCER, 22(2), 250-255 [10.1016/j.clcc.2023.01.003].
Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial)
Tisone, Giuseppe;
2023-06-01
Abstract
background: patients with unresectable colorectal liver metastases (CLM) receiving palliative chemotherapy have a 5-year overall survival (OS) of less than 30%. liver transplantation (LT) can improve OS up to 60%-83% (SECA-I and SECA-II trials). the aim of the study is to assess the efficacy of LT in liver-only metastatic CRC compared with a matched cohort of patients included in a phase III trial on triplet chemotherapy + antiEGFR. patients and methods: the COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial (clinical trials.gov NCT03803436). hyperselected patients with liver-limited unresectable CLM, RAS and BRAF wild-type and curatively removed primary colon cancer are included. the observed post-transplant outcomes will be prospectively compared 1:5 with those obtained in a matched cohort from the TRIPLETE trial (NCT03231722). results: primary endpoint is to compare the 3 and 5-years OS of patients enrolled in the COLT trial with COLT-eligible population enrolled in the TRIPLETE trial. An expected gain in OS of 40% at 5-years is predicted for the COLT population (the expected OS at 5-years in COLT vs. TRIPLETE is 70% vs. 30%). secondary endpoints are to compare the 5-years disease-free survival and to assess the safety of LT dindo-clavien classification and the comprehensive complication Index). conclusion: LT offers the longest OS reported in selected patients with CLM. Improving the selection strategies can give patients a 5-year OS similar to other indications for LT and a better outcome than those undergoing chemotherapy alone.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1533002823000038-main.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
823.12 kB
Formato
Adobe PDF
|
823.12 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.